Any feedback?
Please rate this page
(enzyme.php)
(0/150)

BRENDA support

BRENDA Home
show all | hide all No of entries

Information on EC 3.4.11.20 - aminopeptidase Ey and Organism(s) Plasmodium falciparum and UniProt Accession Q8IL11

for references in articles please use BRENDA:EC3.4.11.20
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
EC Tree
     3 Hydrolases
         3.4 Acting on peptide bonds (peptidases)
             3.4.11 Aminopeptidases
                3.4.11.20 aminopeptidase Ey
Specify your search results
Select one or more organisms in this record: ?
This record set is specific for:
Plasmodium falciparum
UNIPROT: Q8IL11 not found.
Show additional data
Do not include text mining results
Include (text mining) results
Include results (AMENDA + additional results, but less precise)
Word Map
The taxonomic range for the selected organisms is: Plasmodium falciparum
The expected taxonomic range for this enzyme is: Eukaryota, Bacteria
Reaction Schemes
differs from other aminopeptidases in broad specificity for amino acids in the P1 position and the ability to hydrolyse peptides of four or five residues that contain Pro in the P1' position
Synonyms
pfa-m1, pfa-m17, aminopeptidase ey, pf-lap, m1-family aminopeptidase, pfa-m1 aminopeptidase, more
SYNONYM
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
aminopeptidase M17
-
Leucyl aminopeptidase
-
M17 aminopeptidase
-
M17 leucyl aminopeptidase
-
aminopeptidase N
-
-
M1 metalloaminopeptidase
-
-
M1-family aminopeptidase
-
malaria M1 metalloaminopeptidase
-
-
metallo-aminopeptidase M1
-
-
PfA-M1
PfA-M1 aminopeptidase
3 different forms p120, p96, p68
CAS REGISTRY NUMBER
COMMENTARY hide
9031-94-1
-
SUBSTRATE
PRODUCT                       
REACTION DIAGRAM
ORGANISM
UNIPROT
COMMENTARY
(Substrate) hide
LITERATURE
(Substrate)
COMMENTARY
(Product) hide
LITERATURE
(Product)
Reversibility
r=reversible
ir=irreversible
?=not specified
L-Leu-7-amido-4-methyl-coumarin + H2O
L-leucine + 7-amino-4-methyl-coumarin
show the reaction diagram
-
-
-
?
L-leucyl-7-amido-4-methylcoumarin + H2O
L-leucine + 7-amino-4-methylcoumarin
show the reaction diagram
-
-
-
?
Arg-Ala + H2O
L-Arg + L-Ala
show the reaction diagram
-
-
-
-
?
His-Ala + H2O
L-His + L-Ala
show the reaction diagram
-
-
-
-
?
L-Ala 4-nitroanilide + H2O
L-Ala + 4-nitroaniline
show the reaction diagram
-
-
-
?
L-alanyl-2-naphthylamide + H2O
L-alanine + 2-naphthylamine
show the reaction diagram
-
-
-
?
L-Arg 4-nitroanilide + H2O
L-Arg + 4-nitroaniline
show the reaction diagram
-
-
-
?
L-arginyl-2-naphthylamide + H2O
L-arginine + 2-naphthylamine
show the reaction diagram
-
-
-
?
L-Leu 4-nitroanilide + H2O
L-Leu + 4-nitroaniline
show the reaction diagram
-
-
-
?
L-Leu-7-amido-4-methylcoumarin + H2O
L-leucine + 7-amino-4-methylcoumarin
show the reaction diagram
-
-
-
?
L-Leu-p-nitroanilide + H2O
L-Leu + p-nitroaniline
show the reaction diagram
-
-
-
-
?
L-leucyl-7-amido-4-methylcoumarin + H2O
L-leucine + 7-amino-4-methylcoumarin
show the reaction diagram
L-Lys 4-nitroanilide + H2O
L-Lys + 4-nitroaniline
show the reaction diagram
-
-
-
?
Leu-Ala + H2O
L-Leu + L-Ala
show the reaction diagram
-
-
-
-
?
Leu-Gly + H2O
L-Leu + Gly
show the reaction diagram
-
-
-
-
?
Leu-Gly-Gly + H2O
?
show the reaction diagram
-
-
-
-
?
Leu-Gly-Leu + H2O
?
show the reaction diagram
-
-
-
-
?
Leu-Gly-NH2 + H2O
?
show the reaction diagram
-
-
-
-
?
Leu-Gly-Pro + H2O
?
show the reaction diagram
-
-
-
-
?
Leu-Leu + H2O
2 L-Leu
show the reaction diagram
-
-
-
?
Leu-NH2 + H2O
L-Leu + NH3
show the reaction diagram
-
-
-
-
?
Lys-Ala + H2O
L-Lys + L-Ala
show the reaction diagram
-
-
-
-
?
Met-Phe + H2O
L-Met + Phe
show the reaction diagram
-
-
-
?
additional information
?
-
METALS and IONS
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
INHIBITOR
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
(2S,17S,20S,21R)-21-amino-5-(4-benzoylbenzyl)-2-[4-(hex-5-ynoylamino)butyl]-20-hydroxy-17-(naphthalen-2-ylmethyl)-4,7,16,19-tetraoxo-22-phenyl-9,12-dioxa-3,6,15,18-tetraazadocosan-1-amide
-
hPhe-PSI[PO2CH2]-Phe
phosphinic dipeptide analog
N-(1-(4-(1H-pyrazol-1-yl)phenyl)-2-(hydroxyamino)-2-oxoethyl)-3-aminobenzamide
highly effective against the malaria parasites, IC50 values of 233 nM
N-(1-(4-(1H-pyrazol-1-yl)phenyl)-2-(hydroxyamino)-2-oxoethyl)-4-aminobenzamide
highly effective against the malaria parasites, IC50 values of 283 nM
N-(1-(4-(1H-pyrazol-1-yl)phenyl)-2-(hydroxyamino)-2-oxoethyl)-pivalamide
most effective inhibitor of isoform M1 and one of the more potent inhibitors of isoform M17 tested, the most effective compound against 3D7 malaria parasites, with an IC50 of 227 nM
N-[(2-[2-[(N-[(2S,3R)-3-amino-4-[4-(benzyloxy)phenyl]-2-hydroxybutanoyl]-L-alanyl)amino]ethoxy]ethoxy)acetyl]-4-benzoylphenylalanyl-N6-hex-5-ynoyl-L-lysinamide
-
tert-butyl (1-(4-(1H-Pyrazol-1-yl)phenyl)-2-(hydroxyamino)-2-oxoethyl)carbamate
compound shows good in vitro inhibitory properties, but IC50 for parasite growth is only 783 nM, suggesting that compounds substituted with the N-Boc group are either less capable of cellular penetration or less stable than the corresponding N-acyl derivatives
tosedostat
i.e. (2S)-({(2R)-2-[(1S)-1-hydroxy-2-(hydroxyamino)-2-oxoethyl]-4-methylpentanoyl}amino)(phenyl)ethanoic acid, crystal structure
(2S,17S,20S,21R)-21-amino-5-(4-benzoylbenzyl)-2-[4-(hex-5-ynoylamino)butyl]-20-hydroxy-17-(naphthalen-2-ylmethyl)-4,7,16,19-tetraoxo-22-phenyl-9,12-dioxa-3,6,15,18-tetraazadocosan-1-amide
-
1,10-phenanthroline
1 mM, 80% inhibition
1-hydroxy-2-oxo-1,2-dihydro-quinoline-3-carboxylic acid (4-phenyl-butyl)-amide
-
-
1-hydroxy-2-oxo-1,2-dihydro-quinoline-3-carboxylic acid 4-fluoro-benzylamide
-
-
2-(4-benzyl-piperidine-1-carbonyl)-4-methyl-pentanoic acid hydroxyamide
-
-
2-benzyl-3-(3,4-dihydro-1H-isoquinolin-2-yl)-N-hydroxy-3-oxo-propionamide
-
-
2-benzyl-3-(4-benzyl-piperazin-1-yl)-N-hydroxy-3-oxo-propionamide
-
-
2-benzyl-3-(4-benzyl-piperidin-1-yl)-N-hydroxy-3-oxo-propionamide
-
-
2-benzyl-N-(2,2-diphenyl-ethyl)-N'-hydroxy-malonamide
-
-
2-benzyl-N-(4-chloro-benzyl)-N'-hydroxy-malonamide
-
-
2-benzyl-N-(4-fluoro-benzyl)-N'-hydroxy-malonamide
-
-
2-benzyl-N-biphenyl-3-ylmethyl-N'-hydroxy-malonamide
-
-
2-benzyl-N-hydroxy-N'-(2-methyl-benzyl)-malonamide
-
-
2-benzyl-N-hydroxy-N'-(3-phenoxy-benzyl)-malonamide
-
-
2-benzyl-N-hydroxy-N'-(3-phenyl-propyl)-malonamide
-
-
2-benzyl-N-hydroxy-N'-(4-phenyl-butyl)-malonamide
-
-
2-benzyl-N-hydroxy-N'-indan-2-yl-malonamide
-
-
2-benzyl-N-hydroxy-N'-naphthalen-1-ylmethyl-malonamide
-
-
2-benzyl-N-hydroxy-N'-phenethyl-malonamide
-
-
2N-dibenzyl-N'-hydroxy-malonamide
-
-
3-(3,4-dihydro-1H-isoquinolin-2-yl)-N-hydroxy-3-oxo-2-(3-phenoxy-benzyl)-propionamide
-
-
3-(4-benzyl-piperidin-1-yl)-N-hydroxy-3-oxo-2-(3-phenoxybenzyl)-propionamide
-
-
bestatin
bestatin methyl ester
-
N-(1-(4-(1H-pyrazol-1-yl)phenyl)-2-(hydroxyamino)-2-oxoethyl)-3-aminobenzamide
highly effective against the malaria parasites, IC50 values of 233 nM
N-(1-(4-(1H-pyrazol-1-yl)phenyl)-2-(hydroxyamino)-2-oxoethyl)-4-aminobenzamide
highly effective against the malaria parasites, IC50 values of 283 nM
N-(1-(4-(1H-pyrazol-1-yl)phenyl)-2-(hydroxyamino)-2-oxoethyl)-pivalamide
most effective inhibitor of isoform M1 and one of the more potent inhibitors of isoform M17 tested, the most effective compound against 3D7 malaria parasites, with an IC50 of 227 nM
N-(4-chloro-benzyl)-N'-hydroxy-2-(3-phenoxy-benzyl)-malonamide
-
-
N-(4-chloro-benzyl)-N'-hydroxy-2-isobutyl-malonamide
-
-
N-(4-fluoro-benzyl)-N'-hydroxy-2-isobutyl-malonamide
-
-
N-(4-fluoro-benzyl)-N'-hydroxy-2-[1-phenyl-meth-(E)-ylidene]-malonamide
-
-
N-(4-fluoro-benzyl)-N'-hydroxy-2-[1-phenyl-meth-(Z)-ylidene]-malonamide
-
-
N-benzyl-N'-hydroxy-2-(3-phenoxy-benzyl)-malonamide
-
-
N-benzyl-N'-hydroxy-2-isobutyl-malonamide
-
in Tris-HCl buffer (25 mM, pH 7.4), at 25°C
N-hydroxy-2-(3-phenoxy-benzyl)-N'-(3-phenyl-propyl)-malonamide
-
-
N-hydroxy-2-(3-phenoxy-benzyl)-N'-(4-phenyl-butyl)-malonamide
-
-
N-hydroxy-2-(3-phenoxy-benzyl)-N'-(4-trifluoromethyl-benzyl)-malonamide
-
-
N-hydroxy-2-isobutyl-N'-(1,2,3,4-tetrahydro-naphthalen-1-yl)-malonamide
-
-
N-hydroxy-2-isobutyl-N'-(3-phenoxy-benzyl)-malonamide
-
-
N-hydroxy-2-isobutyl-N'-(3-phenyl-propyl)-malonamide
-
-
N-hydroxy-2-isobutyl-N'-(4-phenyl-butyl)-malonamide
-
-
N-hydroxy-2-isobutyl-N'-naphthalen-1-ylmethyl-malonamide
-
-
N-hydroxy-2-isobutyl-N'-phenethyl-malonamide
-
-
N-hydroxy-N'-(4-phenyl-butyl)-2-[1-phenyl-meth-(Z)-ylidene]-malonamide
-
-
N-[(2-[2-[(N-[(2S,3R)-3-amino-4-[4-(benzyloxy)phenyl]-2-hydroxybutanoyl]-L-alanyl)amino]ethoxy]ethoxy)acetyl]-4-benzoylphenylalanyl-N6-hex-5-ynoyl-L-lysinamide
-
N-[(2S,3R)-3-amino-2-hydroxy-4-(4-methoxyphenyl)butanoyl]-L-leucine
-
-
N-[(2S,3R)-3-amino-2-hydroxy-4-(naphthalen-2-yl)butanoyl]-L-leucine
-
-
N-[(2S,3R)-3-amino-2-hydroxy-4-phenylbutanoyl]-L-norleucine
-
-
N-[(2S,3R)-3-amino-2-hydroxyheptanoyl]-L-leucine
-
-
N-[(2S,3R)-3-amino-4-[4-(benzyloxy)phenyl]-2-hydroxybutanoyl]-L-leucine
-
-
N2-[(2S,3R)-3-amino-2-hydroxy-4-phenylbutanoyl]-N6-[(benzyloxy)carbonyl]-L-lysine
-
-
tert-butyl (1-(4-(1H-Pyrazol-1-yl)phenyl)-2-(hydroxyamino)-2-oxoethyl)carbamate
compound shows good in vitro inhibitory properties, but IC50 for parasite growth is only 783 nM, suggesting that compounds substituted with the N-Boc group are either less capable of cellular penetration or less stable than the corresponding N-acyl derivatives
tosedostat
i.e. (2S)-([(2R)-2-[(1S)-1-hydroxy-2-(hydroxyamino)-2-oxoethyl]-4-methylpentanoyl]amino)(phenyl)ethanoic acid, crystal structure
Zn2+
0.1 mM, 80% inhibition
KM VALUE [mM]
SUBSTRATE
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
0.4 - 9
Arg-Ala
4.2 - 35
His-Ala
0.304
L-Ala 4-nitroanilide
pH 7.2, 37°C
0.21 - 4.4
L-alanyl-2-naphthylamide
0.27
L-Arg 4-nitroanilide
pH 7.2, 37°C
0.086 - 1.1
L-arginyl-2-naphthylamide
0.248
L-Lys 4-nitroanilide
pH 7.2, 37°C
0.64 - 10
Leu-Ala
0.95
Leu-Gly
-
pH 7.5, 30°C
0.7
Leu-Gly-Gly
-
pH 7.5, 30°C
0.015
Leu-Gly-Leu
-
pH 7.5, 30°C
0.42
Leu-Gly-NH2
-
pH 7.5, 30°C
0.2
Leu-Gly-Pro
-
pH 7.5, 30°C
0.13 - 1.2
Leu-Leu
4.9
Leu-NH2
-
pH 7.5, 30°C
0.43 - 8.9
Lys-Ala
0.022 - 0.38
Met-Phe
TURNOVER NUMBER [1/s]
SUBSTRATE
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
9.5 - 15
Arg-Ala
1 - 2.4
His-Ala
1.15
L-Ala 4-nitroanilide
pH 7.2, 37°C
3 - 16
L-alanyl-2-naphthylamide
1.58
L-Arg 4-nitroanilide
pH 7.2, 37°C
9.3 - 21
L-arginyl-2-naphthylamide
1.65
L-Leu 4-nitroanilide
pH 7.2, 37°C
1.55
L-Lys 4-nitroanilide
pH 7.2, 37°C
9.3 - 12
Leu-Ala
6.5
Leu-Gly
-
pH 7.5, 30°C
21
Leu-Gly-Gly
-
pH 7.5, 30°C
4.8
Leu-Gly-Leu
-
pH 7.5, 30°C
21
Leu-Gly-NH2
-
pH 7.5, 30°C
12
Leu-Gly-Pro
-
pH 7.5, 30°C
1.4 - 12
Leu-Leu
12
Leu-NH2
-
pH 7.5, 30°C
27
Lys-Ala
5.9 - 7.5
Met-Phe
kcat/KM VALUE [1/mMs-1]
SUBSTRATE
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
1.7 - 23
Arg-Ala
0.027 - 0.56
His-Ala
4.24
L-Ala 4-nitroanilide
pH 7.2, 37°C
3.7 - 170
L-alanyl-2-naphthylamide
5.84
L-Arg 4-nitroanilide
pH 7.2, 37°C
8.7 - 130
L-arginyl-2-naphthylamide
5.42
L-Leu 4-nitroanilide
pH 7.2, 37°C
6.24
L-Lys 4-nitroanilide
pH 7.2, 37°C
1.2 - 14
Leu-Ala
6.8
Leu-Gly
-
pH 7.5, 30°C
30
Leu-Gly-Gly
-
pH 7.5, 30°C
330
Leu-Gly-Leu
-
pH 7.5, 30°C
49
Leu-Gly-NH2
-
pH 7.5, 30°C
60
Leu-Gly-Pro
-
pH 7.5, 30°C
1.2 - 97
Leu-Leu
2.4
Leu-NH2
-
pH 7.5, 30°C
3 - 65
Lys-Ala
19 - 270
Met-Phe
Ki VALUE [mM]
INHIBITOR
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
0.000029
(2S,17S,20S,21R)-21-amino-5-(4-benzoylbenzyl)-2-[4-(hex-5-ynoylamino)butyl]-20-hydroxy-17-(naphthalen-2-ylmethyl)-4,7,16,19-tetraoxo-22-phenyl-9,12-dioxa-3,6,15,18-tetraazadocosan-1-amide
pH 7.5, temperature not specified in the publication
0.000025
bestatin
pH and temperature not specified in the publication
0.000013
hPhe-PSI[PO2CH2]-Phe
pH and temperature not specified in the publication
0.000014
N-(1-(4-(1H-pyrazol-1-yl)phenyl)-2-(hydroxyamino)-2-oxoethyl)-3-aminobenzamide
pH 8.0, 37°C
0.000011
N-(1-(4-(1H-pyrazol-1-yl)phenyl)-2-(hydroxyamino)-2-oxoethyl)-4-aminobenzamide
pH 8.0, 37°C
0.000028
N-(1-(4-(1H-pyrazol-1-yl)phenyl)-2-(hydroxyamino)-2-oxoethyl)-pivalamide
pH 8.0, 37°C
0.004
N-[(2-[2-[(N-[(2S,3R)-3-amino-4-[4-(benzyloxy)phenyl]-2-hydroxybutanoyl]-L-alanyl)amino]ethoxy]ethoxy)acetyl]-4-benzoylphenylalanyl-N6-hex-5-ynoyl-L-lysinamide
pH 7.5, temperature not specified in the publication
0.00003
tert-butyl (1-(4-(1H-Pyrazol-1-yl)phenyl)-2-(hydroxyamino)-2-oxoethyl)carbamate
pH 8.0, 37°C
0.00033
(2S,17S,20S,21R)-21-amino-5-(4-benzoylbenzyl)-2-[4-(hex-5-ynoylamino)butyl]-20-hydroxy-17-(naphthalen-2-ylmethyl)-4,7,16,19-tetraoxo-22-phenyl-9,12-dioxa-3,6,15,18-tetraazadocosan-1-amide
pH 7.5, temperature not specified in the publication
0.00012 - 0.0038
bestatin
0.00048
bestatin methyl ester
0.0055
N-(1-(4-(1H-pyrazol-1-yl)phenyl)-2-(hydroxyamino)-2-oxoethyl)-3-aminobenzamide
pH 8.0, 37°C
0.0074
N-(1-(4-(1H-pyrazol-1-yl)phenyl)-2-(hydroxyamino)-2-oxoethyl)-4-aminobenzamide
pH 8.0, 37°C
0.0007
N-(1-(4-(1H-pyrazol-1-yl)phenyl)-2-(hydroxyamino)-2-oxoethyl)-pivalamide
pH 8.0, 37°C
0.00026
N-[(2-[2-[(N-[(2S,3R)-3-amino-4-[4-(benzyloxy)phenyl]-2-hydroxybutanoyl]-L-alanyl)amino]ethoxy]ethoxy)acetyl]-4-benzoylphenylalanyl-N6-hex-5-ynoyl-L-lysinamide
pH 7.5, temperature not specified in the publication
0.000043
N-[(2S,3R)-3-amino-2-hydroxy-4-(4-methoxyphenyl)butanoyl]-L-leucine
-
pH 7.5, temperature not specified in the publication
0.003
N-[(2S,3R)-3-amino-2-hydroxy-4-(naphthalen-2-yl)butanoyl]-L-leucine
-
pH 7.5, temperature not specified in the publication
0.0009
N-[(2S,3R)-3-amino-2-hydroxy-4-phenylbutanoyl]-L-norleucine
-
pH 7.5, temperature not specified in the publication
0.0053
N-[(2S,3R)-3-amino-2-hydroxyheptanoyl]-L-leucine
-
pH 7.5, temperature not specified in the publication
0.00049
N-[(2S,3R)-3-amino-4-[4-(benzyloxy)phenyl]-2-hydroxybutanoyl]-L-leucine
-
pH 7.5, temperature not specified in the publication
0.00145
N2-[(2S,3R)-3-amino-2-hydroxy-4-phenylbutanoyl]-N6-[(benzyloxy)carbonyl]-L-lysine
-
pH 7.5, temperature not specified in the publication
0.0008
tert-butyl (1-(4-(1H-Pyrazol-1-yl)phenyl)-2-(hydroxyamino)-2-oxoethyl)carbamate
pH 8.0, 37°C
IC50 VALUE [mM]
INHIBITOR
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
0.01
1-hydroxy-2-oxo-1,2-dihydro-quinoline-3-carboxylic acid (4-phenyl-butyl)-amide
Plasmodium falciparum
-
IC50 above 0.01 mM, in Tris-HCl buffer (25 mM, pH 7.4), at 25°C
0.01
1-hydroxy-2-oxo-1,2-dihydro-quinoline-3-carboxylic acid 4-fluoro-benzylamide
Plasmodium falciparum
-
IC50 above 0.01 mM, in Tris-HCl buffer (25 mM, pH 7.4), at 25°C
0.000406
2-(4-benzyl-piperidine-1-carbonyl)-4-methyl-pentanoic acid hydroxyamide
Plasmodium falciparum
-
in Tris-HCl buffer (25 mM, pH 7.4), at 25°C
0.000253
2-benzyl-3-(3,4-dihydro-1H-isoquinolin-2-yl)-N-hydroxy-3-oxo-propionamide
Plasmodium falciparum
-
in Tris-HCl buffer (25 mM, pH 7.4), at 25°C
0.00176
2-benzyl-3-(4-benzyl-piperazin-1-yl)-N-hydroxy-3-oxo-propionamide
Plasmodium falciparum
-
in Tris-HCl buffer (25 mM, pH 7.4), at 25°C
0.000206
2-benzyl-3-(4-benzyl-piperidin-1-yl)-N-hydroxy-3-oxo-propionamide
Plasmodium falciparum
-
in Tris-HCl buffer (25 mM, pH 7.4), at 25°C
0.005363
2-benzyl-N-(2,2-diphenyl-ethyl)-N'-hydroxy-malonamide
Plasmodium falciparum
-
in Tris-HCl buffer (25 mM, pH 7.4), at 25°C
0.00017
2-benzyl-N-(4-chloro-benzyl)-N'-hydroxy-malonamide
Plasmodium falciparum
-
in Tris-HCl buffer (25 mM, pH 7.4), at 25°C
0.000027
2-benzyl-N-(4-fluoro-benzyl)-N'-hydroxy-malonamide
Plasmodium falciparum
-
in Tris-HCl buffer (25 mM, pH 7.4), at 25°C
0.001168
2-benzyl-N-biphenyl-3-ylmethyl-N'-hydroxy-malonamide
Plasmodium falciparum
-
in Tris-HCl buffer (25 mM, pH 7.4), at 25°C
0.000041
2-benzyl-N-hydroxy-N'-(2-methyl-benzyl)-malonamide
Plasmodium falciparum
-
in Tris-HCl buffer (25 mM, pH 7.4), at 25°C
0.002515
2-benzyl-N-hydroxy-N'-(3-phenoxy-benzyl)-malonamide
Plasmodium falciparum
-
in Tris-HCl buffer (25 mM, pH 7.4), at 25°C
0.000125
2-benzyl-N-hydroxy-N'-(3-phenyl-propyl)-malonamide
Plasmodium falciparum
-
in Tris-HCl buffer (25 mM, pH 7.4), at 25°C
0.000046
2-benzyl-N-hydroxy-N'-(4-phenyl-butyl)-malonamide
Plasmodium falciparum
-
in Tris-HCl buffer (25 mM, pH 7.4), at 25°C
0.001931
2-benzyl-N-hydroxy-N'-indan-2-yl-malonamide
Plasmodium falciparum
-
in Tris-HCl buffer (25 mM, pH 7.4), at 25°C
0.000107
2-benzyl-N-hydroxy-N'-naphthalen-1-ylmethyl-malonamide
Plasmodium falciparum
-
in Tris-HCl buffer (25 mM, pH 7.4), at 25°C
0.001011
2-benzyl-N-hydroxy-N'-phenethyl-malonamide
Plasmodium falciparum
-
in Tris-HCl buffer (25 mM, pH 7.4), at 25°C
0.000125
2N-dibenzyl-N'-hydroxy-malonamide
Plasmodium falciparum
-
in Tris-HCl buffer (25 mM, pH 7.4), at 25°C
0.000966
3-(3,4-dihydro-1H-isoquinolin-2-yl)-N-hydroxy-3-oxo-2-(3-phenoxy-benzyl)-propionamide
Plasmodium falciparum
-
in Tris-HCl buffer (25 mM, pH 7.4), at 25°C
0.000248
3-(4-benzyl-piperidin-1-yl)-N-hydroxy-3-oxo-2-(3-phenoxybenzyl)-propionamide
Plasmodium falciparum
-
in Tris-HCl buffer (25 mM, pH 7.4), at 25°C
0.00013
N-(4-chloro-benzyl)-N'-hydroxy-2-(3-phenoxy-benzyl)-malonamide
Plasmodium falciparum
-
in Tris-HCl buffer (25 mM, pH 7.4), at 25°C
0.000904
N-(4-chloro-benzyl)-N'-hydroxy-2-isobutyl-malonamide
Plasmodium falciparum
-
in Tris-HCl buffer (25 mM, pH 7.4), at 25°C
0.003896
N-(4-fluoro-benzyl)-N'-hydroxy-2-isobutyl-malonamide
Plasmodium falciparum
-
in Tris-HCl buffer (25 mM, pH 7.4), at 25°C
0.00033
N-(4-fluoro-benzyl)-N'-hydroxy-2-[1-phenyl-meth-(E)-ylidene]-malonamide
Plasmodium falciparum
-
in Tris-HCl buffer (25 mM, pH 7.4), at 25°C
0.000006
N-(4-fluoro-benzyl)-N'-hydroxy-2-[1-phenyl-meth-(Z)-ylidene]-malonamide
Plasmodium falciparum
-
in Tris-HCl buffer (25 mM, pH 7.4), at 25°C
0.000164
N-benzyl-N'-hydroxy-2-(3-phenoxy-benzyl)-malonamide
Plasmodium falciparum
-
in Tris-HCl buffer (25 mM, pH 7.4), at 25°C
0.000495
N-benzyl-N'-hydroxy-2-isobutyl-malonamide
Plasmodium falciparum
-
in Tris-HCl buffer (25 mM, pH 7.4), at 25°C
0.000527
N-hydroxy-2-(3-phenoxy-benzyl)-N'-(3-phenyl-propyl)-malonamide
Plasmodium falciparum
-
in Tris-HCl buffer (25 mM, pH 7.4), at 25°C
0.000225
N-hydroxy-2-(3-phenoxy-benzyl)-N'-(4-phenyl-butyl)-malonamide
Plasmodium falciparum
-
in Tris-HCl buffer (25 mM, pH 7.4), at 25°C
0.000231
N-hydroxy-2-(3-phenoxy-benzyl)-N'-(4-trifluoromethyl-benzyl)-malonamide
Plasmodium falciparum
-
in Tris-HCl buffer (25 mM, pH 7.4), at 25°C
0.000109
N-hydroxy-2-isobutyl-N'-(1,2,3,4-tetrahydro-naphthalen-1-yl)-malonamide
Plasmodium falciparum
-
in Tris-HCl buffer (25 mM, pH 7.4), at 25°C
0.000045
N-hydroxy-2-isobutyl-N'-(3-phenoxy-benzyl)-malonamide
Plasmodium falciparum
-
in Tris-HCl buffer (25 mM, pH 7.4), at 25°C
0.00079
N-hydroxy-2-isobutyl-N'-(3-phenyl-propyl)-malonamide
Plasmodium falciparum
-
in Tris-HCl buffer (25 mM, pH 7.4), at 25°C
0.001149
N-hydroxy-2-isobutyl-N'-(4-phenyl-butyl)-malonamide
Plasmodium falciparum
-
in Tris-HCl buffer (25 mM, pH 7.4), at 25°C
0.000091
N-hydroxy-2-isobutyl-N'-naphthalen-1-ylmethyl-malonamide
Plasmodium falciparum
-
in Tris-HCl buffer (25 mM, pH 7.4), at 25°C
0.000885
N-hydroxy-2-isobutyl-N'-phenethyl-malonamide
Plasmodium falciparum
-
in Tris-HCl buffer (25 mM, pH 7.4), at 25°C
0.000013
N-hydroxy-N'-(4-phenyl-butyl)-2-[1-phenyl-meth-(Z)-ylidene]-malonamide
Plasmodium falciparum
-
in Tris-HCl buffer (25 mM, pH 7.4), at 25°C
pH OPTIMUM
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
pH RANGE
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
5.5 - 9.5
pure native enzyme, substrate L-Leu-7-amido-4-methylcoumarin
ORGANISM
COMMENTARY hide
LITERATURE
UNIPROT
SEQUENCE DB
SOURCE
SOURCE TISSUE
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
SOURCE
LOCALIZATION
ORGANISM
UNIPROT
COMMENTARY hide
GeneOntology No.
LITERATURE
SOURCE
intraerythroytic parasite
Manually annotated by BRENDA team
GENERAL INFORMATION
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
malfunction
inhibition is lethal to parasites early in the life cycle, prior to the onset of hemoglobin degradation
malfunction
inhibition caused swelling of the parasite digestive vacuole and prevented proteolysis of hemoglobin derived oligopeptides, likely starving the parasite resulting in death
physiological function
synthesized as the precursor p120 form, targeted to the parasitophorous vacuole via the parasite endoplasmic reticulum/Golgi, where it is converted into the transient p96 form; p96 form is eventually redirected into the parasite to be converted into the processed p68 form that is only marginally delivered to the parasite foodvacuole
MOLECULAR WEIGHT
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
343000
gel filtration
106130
x * 106130, calculated for recombinant protein including His-tag
120000
x * 120000, x * complex of 68000 and 35000 (generated by proteolytic cleveage within the loop sequence containing Leu-796 without N-terminal extension (residue 1-194))
SUBUNIT
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
homohexamer
CRYSTALLIZATION (Commentary)
ORGANISM
UNIPROT
LITERATURE
hanging drop vapour diffusion method
in complex with inhibitor tosedostat. The inhibitor occupies the enzymes' putative product egress channels in addition to the substrate binding pockets. Inhibitor adopts different binding poses when bound to isoforms M1, and M17
in complex with inhibitor tosedostat. The inhibitor occupies the enzymes' putative product egress channels in addition to the substrate binding pockets. Inhibitor adopts different binding poses when bound to isoforms M1, and M17
PROTEIN VARIANTS
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
additional information
pH STABILITY
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
5 - 8.5
at least 90% activity after 60 min
717834
PURIFICATION (Commentary)
ORGANISM
UNIPROT
LITERATURE
immobilized metal ion affinity chromatography (Ni2+), gel filtration
amino acid residue 192-1085 as His-tagged protein: immobilized metal ion affinity chromatography (Ni2+), His-tag removed, gel filtration
from a modified parasite line expressing an enzyme with a C-terminal hemagglutinin tag: ion exchange chromatography, gel filtration
p68 form, immobilized metal ion affinity chromatography (Ni2+)
CLONED (Commentary)
ORGANISM
UNIPROT
LITERATURE
expression in Escherichia coli
His-tagged protein (amino acid residue 79-605) expressed in Escherichia coli
His-tagged truncated form expressed in Escherichia coli Rosetta2 BL21(DE3)
amino acid residue 192-1085 expressed in Escherichia coli
expressed in Escherichia coli
-
expression in Escherichia coli
His-tagged p68 form expressed in Escherichia coli BL21(DE3)
EXPRESSION
ORGANISM
UNIPROT
LITERATURE
p120 form is expressed in ring stages at least 12 hours before p68 is detected
REF.
AUTHORS
TITLE
JOURNAL
VOL.
PAGES
YEAR
ORGANISM (UNIPROT)
PUBMED ID
SOURCE
Flipo, M.; Beghyn, T.; Leroux, V.; Florent, I.; Deprez, B.P.; Deprez-Poulain, R.F.
Novel selective inhibitors of the zinc plasmodial aminopeptidase PfA-M1 as potential antimalarial agents
J. Med. Chem.
50
1322-1334
2007
Plasmodium falciparum, Plasmodium falciparum FcB1
Manually annotated by BRENDA team
Ragheb, D.; Dalal, S.; Bompiani, K.M.; Ray, W.K.; Klemba, M.
Distribution and biochemical properties of an M1-family aminopeptidase in Plasmodium falciparum indicate a role in vacuolar hemoglobin catabolism
J. Biol. Chem.
286
27255-27265
2011
Plasmodium falciparum (Q8IEK1), Plasmodium falciparum
Manually annotated by BRENDA team
Velmourougane, G.; Harbut, M.B.; Dalal, S.; McGowan, S.; Oellig, C.A.; Meinhardt, N.; Whisstock, J.C.; Klemba, M.; Greenbaum, D.C.
Synthesis of new (-)-bestatin-based inhibitor libraries reveals a novel binding mode in the S1 pocket of the essential malaria M1 metalloaminopeptidase
J. Med. Chem.
54
1655-1666
2011
Plasmodium falciparum
Manually annotated by BRENDA team
Azimzadeh, O.; Sow, C.; Geze, M.; Nyalwidhe, J.; Florent, I.
Plasmodium falciparum PfA-M1 aminopeptidase is trafficked via the parasitophorous vacuole and marginally delivered to the food vacuole
Malar. J.
9
189
2010
Plasmodium falciparum (O96935), Plasmodium falciparum
Manually annotated by BRENDA team
McGowan, S.; Oellig, C.A.; Birru, W.A.; Caradoc-Davies, T.T.; Stack, C.M.; Lowther, J.; Skinner-Adams, T.; Mucha, A.; Kafarski, P.; Grembecka, J.; Trenholme, K.R.; Buckle, A.M.; Gardiner, D.L.; Dalton, J.P.; Whisstock, J.C.
Structure of the Plasmodium falciparum M17 aminopeptidase and significance for the design of drugs targeting the neutral exopeptidases
Proc. Natl. Acad. Sci. USA
107
2449-2454
2010
Plasmodium falciparum (Q8IL11), Plasmodium falciparum
Manually annotated by BRENDA team
Harbut, M.B.; Velmourougane, G.; Dalal, S.; Reiss, G.; Whisstock, J.C.; Onder, O.; Brisson, D.; McGowan, S.; Klemba, M.; Greenbaum, D.C.
Bestatin-based chemical biology strategy reveals distinct roles for malaria M1- and M17-family aminopeptidases
Proc. Natl. Acad. Sci. USA
108
E526-E534
2011
Plasmodium falciparum, Plasmodium falciparum (Q8IL11)
Manually annotated by BRENDA team
Mistry, S.N.; Drinkwater, N.; Ruggeri, C.; Sivaraman, K.K.; Loganathan, S.; Fletcher, S.; Drag, M.; Paiardini, A.; Avery, V.M.; Scammells, P.J.; McGowan, S.
Two-pronged attack: dual inhibition of Plasmodium falciparum M1 and M17 metalloaminopeptidases by a novel series of hydroxamic acid-based inhibitors
J. Med. Chem.
57
9168-9183
2014
Plasmodium falciparum (O96935), Plasmodium falciparum (Q8IL11), Plasmodium falciparum, Plasmodium falciparum isolate FcB1/Columbia (O96935)
Manually annotated by BRENDA team
Dalal, S.; Ragheb, D.R.; Klemba, M.
Engagement of the S1, S1' and S2' subsites drives efficient catalysis of peptide bond hydrolysis by the M1-family aminopeptidase from Plasmodium falciparum
Mol. Biochem. Parasitol.
183
70-77
2012
Plasmodium falciparum
Manually annotated by BRENDA team
Gonzalez-Bacerio, J.; Osuna, J.; Ponce, A.; Fando, R.; Figarella, K.; Mendez, Y.; Charli, J.L.; Chavez, M.D.
High-level expression in Escherichia coli, purification and kinetic characterization of Plasmodium falciparum M1-aminopeptidase
Protein Expr. Purif.
104C
103-114
2014
Plasmodium falciparum (Q8IEK1)
Manually annotated by BRENDA team
Drinkwater, N.; Bamert, R.S.; Kannan Sivaraman, K.; Paiardini, A.; McGowan, S.
X-ray crystal structures of an orally available aminopeptidase inhibitor, tosedostat, bound to anti-malarial drug targets PfA-M1 and PfA-M17
Proteins
83
789-795
2015
Plasmodium falciparum (O96935), Plasmodium falciparum (Q8IL11), Plasmodium falciparum, Plasmodium falciparum isolate FcB1/Columbia (O96935)
Manually annotated by BRENDA team